China Biotech Services Holdings Limited announced a restructuring of its previously disclosed Share Award Scheme. Under a newly signed Tripartite Agreement dated 13 May 2026, employee partnership Jiabao Zhongzhi (Hainan) will subscribe RMB9.30 million for 5.84% of the registered capital of subsidiary Pengbo (Hainan), replacing the earlier plan to take 9% of Dynamic Healthcare.

Upon completion, China Biotech Services will retain 94.16% of Pengbo (Hainan); control of the subsidiary, and therefore group consolidation, remain unchanged. The subscription proceeds will serve as general working capital for Pengbo (Hainan), which focuses on boron neutron capture therapy (BNCT) services.

Pengbo (Hainan) posted revenue of RMB0.13 million in 2025 (2024: RMB0.07 million) and recorded an audited net loss after tax of RMB28.60 million (2024: RMB22.49 million). Audited net assets stood at RMB83.75 million as of 31 December 2025. Pre-subscription registered capital totals RMB150.00 million.

The transaction is classified as a connected transaction at the subsidiary level under GEM Listing Rule 20.99 but is exempt from circular, independent financial advice and independent shareholders’ approval requirements because all percentage ratios are below 5%, terms are on normal commercial conditions, and the board (including independent non-executive directors) has approved the deal as fair and reasonable.

No gain or loss will be recognized in the consolidated financial statements, as the agreement is treated as an equity transaction with no loss of control over Pengbo (Hainan).